Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues

AIDS Res Hum Retroviruses. 2016 Apr;32(4):334-8. doi: 10.1089/AID.2015.0315. Epub 2016 Jan 29.

Abstract

The potential of maraviroc (MVC), a small-molecule CCR5 antagonist, as a candidate to prevent HIV-1 sexual transmission by oral or topical dosing has not yet been completely established. Using relevant cellular and mucosal tissue explant models, we show partial antiviral activity of MVC when tested in multiple preclinical dosing strategies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / pharmacology
  • Cells, Cultured
  • Cyclohexanes / administration & dosage*
  • Cyclohexanes / pharmacology
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • HIV-1 / isolation & purification*
  • Humans
  • Maraviroc
  • Models, Biological
  • Mucous Membrane / virology*
  • Organ Culture Techniques
  • Treatment Outcome
  • Triazoles / administration & dosage*
  • Triazoles / pharmacology

Substances

  • Anti-HIV Agents
  • Cyclohexanes
  • Triazoles
  • Maraviroc